{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:05:58Z","timestamp":1793066758035,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bcp.2020.114149","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T23:23:58Z","timestamp":1594509838000},"page":"114149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review"],"prefix":"10.1016","volume":"181","author":[{"given":"Axel H.","family":"Sch\u00f6nthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis S.","family":"Markland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114149_b0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.toxicon.2012.09.008","article-title":"Non-enzymatic proteins from snake venoms: a gold mine of pharmacological tools and drug leads","volume":"62","author":"McCleary","year":"2013","journal-title":"Toxicon"},{"issue":"11","key":"10.1016\/j.bcp.2020.114149_b0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/toxins10110474","article-title":"Snake venom peptides: tools of biodiscovery","volume":"10","author":"Munawar","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/toxins10010008","article-title":"Computational studies of snake venom toxins","volume":"10","author":"Ojeda","year":"2017","journal-title":"Toxins (Basel)"},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/toxins9090290","article-title":"A review and database of snake venom proteomes","volume":"9","author":"Tasoulis","year":"2017","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.bcp.2020.114149_b0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.toxicon.2012.09.005","article-title":"The continuing saga of snake venom disintegrins","volume":"62","author":"Calvete","year":"2013","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.bcp.2020.114149_b0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/B:THRO.0000003308.63022.8d","article-title":"Comparative pharmacology of GP IIb\/IIIa antagonists","volume":"15","author":"Schror","year":"2003","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0035","first-page":"192","article-title":"Chemical structures and mode of action of intravenous glycoprotein IIb\/IIIa receptor blockers: a review","volume":"13","author":"Hashemzadeh","year":"2008","journal-title":"Exp. Clin. Cardiol."},{"issue":"15","key":"10.1016\/j.bcp.2020.114149_b0040","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1016\/S0021-9258(18)92826-7","article-title":"Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri","volume":"266","author":"Scarborough","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"9148","key":"10.1016\/j.bcp.2020.114149_b0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet GPIIb-IIIa blockers","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.bcp.2020.114149_b0050","doi-asserted-by":"crossref","first-page":"19827","DOI":"10.1016\/S0021-9258(19)77710-2","article-title":"Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus","volume":"263","author":"Gan","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114149_b0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jebm.12253","article-title":"Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: a systematic review and meta-analysis","volume":"10","author":"Zhou","year":"2017","journal-title":"J. Evid. Based Med."},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.toxicon.2011.03.017","article-title":"From snake venom toxins to therapeutics\u2013cardiovascular examples","volume":"59","author":"Koh","year":"2012","journal-title":"Toxicon"},{"issue":"14","key":"10.1016\/j.bcp.2020.114149_b0065","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1007\/s00253-016-7610-9","article-title":"Snake venom toxins: toxicity and medicinal applications","volume":"100","author":"Chan","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"17","key":"10.1016\/j.bcp.2020.114149_b0070","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.2174\/0929867324666170605091546","article-title":"Snake venom: from deadly toxins to life-saving therapeutics","volume":"24","author":"Waheed","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cancers9090110","article-title":"Integrins as therapeutic targets: successes and cancers","volume":"9","author":"Raab-Westphal","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-018-0937-3","article-title":"The functional role of integrins during intra- and extravasation within the metastatic cascade","volume":"18","author":"Sokeland","year":"2019","journal-title":"Mol. Cancer"},{"issue":"22","key":"10.1016\/j.bcp.2020.114149_b0095","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2174\/138161206777947713","article-title":"Integrins in drug targeting-RGD templates in toxins","volume":"12","author":"Lu","year":"2006","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.bcp.2020.114149_b0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-2712(18)30514-6","article-title":"Structural and biologic properties of integrin-mediated cell adhesion","volume":"12","author":"Cheresh","year":"1992","journal-title":"Clin. Lab. Med."},{"issue":"4826","key":"10.1016\/j.bcp.2020.114149_b0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1126\/science.2821619","article-title":"New perspectives in cell adhesion: RGD and integrins","volume":"238","author":"Ruoslahti","year":"1987","journal-title":"Science"},{"issue":"5963","key":"10.1016\/j.bcp.2020.114149_b0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/309030a0","article-title":"Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule","volume":"309","author":"Pierschbacher","year":"1984","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0115","doi-asserted-by":"crossref","first-page":"183206","DOI":"10.1016\/j.bbamem.2020.183206","article-title":"Chapter 22: structural and signaling functions of integrins","volume":"1862","author":"Kadry","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Biomembr."},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers9090116","article-title":"Exploring the role of RGD-recognizing integrins in cancer","volume":"9","author":"Nieberler","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm2593","article-title":"Environmental sensing through focal adhesions","volume":"10","author":"Geiger","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0135","first-page":"4","article-title":"Role of integrins and other cell adhesion molecules in tumor progression and metastasis","volume":"68","author":"Albelda","year":"1993","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.bcp.2020.114149_b0145","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1073\/pnas.92.16.7411","article-title":"Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells","volume":"92","author":"Zutter","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0150","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1152\/physrev.00036.2018","article-title":"Cell adhesion by integrins","volume":"99","author":"Bachmann","year":"2019","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0155","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jcb.22427","article-title":"Structural basis of integrin transmembrane activation","volume":"109","author":"Wang","year":"2010","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0160","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2174\/1389203716666150515125002","article-title":"Disintegrins from snake venoms and their applications in cancer research and therapy","volume":"16","author":"Arruda Macedo","year":"2015","journal-title":"Curr. Protein Pept. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2020.114149_b0165","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.toxicon.2005.02.024","article-title":"Snake venom disintegrins: evolution of structure and function","volume":"45","author":"Calvete","year":"2005","journal-title":"Toxicon"},{"issue":"8","key":"10.1016\/j.bcp.2020.114149_b0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/toxins10080321","article-title":"Recombinant and chimeric disintegrins in preclinical research","volume":"10","author":"David","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.toxicon.2011.07.004","article-title":"Non-RGD-containing snake venom disintegrins, functional and structural relations","volume":"58","author":"Walsh","year":"2011","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0180","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1021\/bi015627o","article-title":"The presence of the WGD motif in CC8 heterodimeric disintegrin increases its inhibitory effect on alphaII(b)beta3, alpha(v)beta3, and alpha5beta1 integrins","volume":"41","author":"Calvete","year":"2002","journal-title":"Biochemistry"},{"issue":"Pt 3","key":"10.1016\/j.bcp.2020.114149_b0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj20021739","article-title":"Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering","volume":"372","author":"Calvete","year":"2003","journal-title":"Biochem. J."},{"issue":"5565","key":"10.1016\/j.bcp.2020.114149_b0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1126\/science.1069040","article-title":"Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand","volume":"296","author":"Xiong","year":"2002","journal-title":"Science"},{"issue":"53","key":"10.1016\/j.bcp.2020.114149_b0195","doi-asserted-by":"crossref","first-page":"37809","DOI":"10.1074\/jbc.274.53.37809","article-title":"Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins","volume":"274","author":"Wierzbicka-Patynowski","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"33","key":"10.1016\/j.bcp.2020.114149_b0200","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1016\/S0021-9258(18)47710-1","article-title":"Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex","volume":"262","author":"Huang","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bcp.2020.114149_b0205","first-page":"4993","article-title":"Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis","volume":"54","author":"Trikha","year":"1994","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0049-3848(94)90052-3","article-title":"Purification and characterization of platelet aggregation inhibitors from snake venoms","volume":"73","author":"Trikha","year":"1994","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0215","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.toxicon.2011.02.020","article-title":"Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential","volume":"59","author":"Minea","year":"2012","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1359\/jbmr.1998.13.3.409","article-title":"Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment","volume":"13","author":"Mercer","year":"1998","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bcp.2020.114149_b0225","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/abbi.1999.1682","article-title":"Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom","volume":"375","author":"Zhou","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0230","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/bbrc.1999.1965","article-title":"Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5","volume":"267","author":"Zhou","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0235","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:AGEN.0000021396.47009.b0","article-title":"Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom","volume":"6","author":"Golubkov","year":"2003","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1009059210733","article-title":"Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis","volume":"3","author":"Zhou","year":"1999","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1006457903545","article-title":"Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression","volume":"61","author":"Zhou","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"issue":"28","key":"10.1016\/j.bcp.2020.114149_b0250","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.2174\/138161207782023793","article-title":"Anti-angiogenesis and RGD-containing snake venom disintegrins","volume":"13","author":"Swenson","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2020.114149_b0255","first-page":"63","article-title":"Synthesis of linear, branched, and cyclic peptide chimera","volume":"298","author":"Mezo","year":"2005","journal-title":"Methods Mol. Biol."},{"issue":"3\u20136","key":"10.1016\/j.bcp.2020.114149_b0260","first-page":"177","article-title":"New insights on disintegrin-receptor interactions: eristostatin and melanoma cells","volume":"31","author":"McLane","year":"2001","journal-title":"Haemostasis"},{"issue":"2","key":"10.1016\/j.bcp.2020.114149_b0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/156800906776056518","article-title":"Integrins in cancer treatment","volume":"6","author":"Eble","year":"2006","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0270","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4155\/fmc-2017-0008","article-title":"RGD-mediated delivery of small-molecule drugs","volume":"9","author":"Katsamakas","year":"2017","journal-title":"Future Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010929","article-title":"Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities","volume":"5","author":"Minea","year":"2010","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.bcp.2020.114149_b0280","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1021\/bm401622y","article-title":"Multimeric disintegrin protein polymer fusions that target tumor vasculature","volume":"15","author":"Janib","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bcp.2020.114149_b0285","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1021\/jm5000547","article-title":"Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists","volume":"57","author":"Sheldrake","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0290","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2020.114149_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0300","first-page":"18","article-title":"Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments","volume":"8","author":"Testa","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0305","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bcp.2020.114149_b0310","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919880429","article-title":"Novel therapeutic avenues in triple-negative breast cancer: PI3K\/AKT inhibition, androgen receptor blockade, and beyond","volume":"11","author":"Chan","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0315","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/a-0842-6661","article-title":"Update breast cancer 2019 Part 2 - implementation of novel diagnostics and therapeutics in advanced breast cancer patients in clinical practice","volume":"79","author":"Janni","year":"2019","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.bcp.2020.114149_b0320","doi-asserted-by":"crossref","unstructured":"E. Mezni C. Vicier M. Guerin R. Sabatier F. Bertucci A. Goncalves New therapeutics in HER2-positive advanced breast cancer: towards a change in clinical practices? Cancers (Basel) 12(6) (2020) E1573.","DOI":"10.3390\/cancers12061573"},{"key":"10.1016\/j.bcp.2020.114149_b0325","unstructured":"American Cancer Society. Cancer Facts & Figures 2020, American Cancer Society (2020)."},{"issue":"3\u20136","key":"10.1016\/j.bcp.2020.114149_b0330","first-page":"183","article-title":"A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model","volume":"31","author":"Markland","year":"2001","journal-title":"Haemostasis"},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0335","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.499.3.4","article-title":"Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression","volume":"3","author":"Swenson","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"3\u20136","key":"10.1016\/j.bcp.2020.114149_b0340","first-page":"192","article-title":"Viper venom components affecting angiogenesis","volume":"31","author":"Huang","year":"2001","journal-title":"Haemostasis"},{"issue":"15","key":"10.1016\/j.bcp.2020.114149_b0345","first-page":"3754","article-title":"A novel disintegrin salmosin inhibits tumor angiogenesis","volume":"59","author":"Kang","year":"1999","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2020.114149_b0350","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/labinvest.3700350","article-title":"A.A.Lebestatin, a disintegrin from Macrovipera venom, inhibits integrin-mediated cell adhesion, migration and angiogenesis","volume":"85","author":"Olfa","year":"2005","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10585-007-9101-y","article-title":"A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis","volume":"25","author":"Ramos","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bcp.2020.114149_b0360","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ijbiomac.2019.01.073","article-title":"The anticancer properties and mechanism of action of tablysin-15, the RGD-containing disintegrin, in breast cancer cells","volume":"129","author":"Deng","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0365","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.toxicon.2005.01.013","article-title":"Inhibition of tumor formation by snake venom disintegrin","volume":"45","author":"Yang","year":"2005","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0370","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxicon.2012.03.011","article-title":"Anti-invasive and anti-adhesive activities of a recombinant disintegrin, r-viridistatin 2, derived from the Prairie rattlesnake (Crotalus viridis viridis)","volume":"60","author":"Lucena","year":"2012","journal-title":"Toxicon"},{"issue":"22","key":"10.1016\/j.bcp.2020.114149_b0375","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2174\/1568026619666190806151401","article-title":"Antitumoral potential of lansbermin-i, a novel disintegrin from porthidium lansbergii lansbergii venom on breast cancer cells","volume":"19","author":"Montealegre-Sanchez","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0380","first-page":"7496","article-title":"Temporal trends and racial disparities in global prostate cancer prevalence","volume":"21","author":"Rebbeck","year":"2014","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.bcp.2020.114149_b0385","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-020-0222-6","article-title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","author":"Mori","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"44","key":"10.1016\/j.bcp.2020.114149_b0390","doi-asserted-by":"crossref","first-page":"e17748","DOI":"10.1097\/MD.0000000000017748","article-title":"Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"98","author":"Zheng","year":"2019","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.bcp.2020.114149_b0395","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.urolonc.2018.07.020","article-title":"The addition of chemotherapy in the definitive management of high risk prostate cancer","volume":"36","author":"Ferris","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bcp.2020.114149_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102864","article-title":"Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: a review","volume":"146","author":"Cursano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.bcp.2020.114149_b0405","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.3390\/ijms20112676","article-title":"Targeting angiogenesis in prostate cancer","volume":"20","author":"Melegh","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0410","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41585-020-0298-8","article-title":"Cellular rewiring in lethal prostate cancer: the architect of drug resistance","volume":"17","author":"Carceles-Cordon","year":"2020","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0415","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/pros.23729","article-title":"Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting","volume":"79","author":"Miyahira","year":"2019","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0420","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2045-824X-5-19","article-title":"The effects of radiation on angiogenesis","volume":"5","author":"Grabham","year":"2013","journal-title":"Vasc. Cell"},{"issue":"17","key":"10.1016\/j.bcp.2020.114149_b0425","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-04-1223","article-title":"Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy","volume":"11","author":"Abdollahi","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"42","key":"10.1016\/j.bcp.2020.114149_b0430","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1038\/sj.onc.1210429","article-title":"Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling","volume":"26","author":"McCabe","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0435","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2015.05.018","article-title":"Avbeta3 integrin: pathogenetic role in osteotropic tumors","volume":"96","author":"Stucci","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"21","key":"10.1016\/j.bcp.2020.114149_b0440","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/0008-5472.CAN-17-0064","article-title":"Tenascin-C and integrin alpha9 mediate interactions of prostate cancer with the bone microenvironment","volume":"77","author":"San Martin","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0445","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1158\/1541-7786.MCR-19-0278","article-title":"A PSCA\/PGRN-NF-kappaB-integrin-alpha4 axis promotes prostate cancer cell Adhesion to bone marrow endothelium and enhances metastatic potential","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2020.114149_b0450","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1476-4598-13-208","article-title":"Induction of integrin alpha2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture","volume":"13","author":"Ziaee","year":"2014","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0455","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/ERC-08-0019","article-title":"Integrins in prostate cancer progression","volume":"15","author":"Goel","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2020.114149_b0460","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers10020044","article-title":"Integrin inhibitors in prostate cancer","volume":"10","author":"Juan-Rivera","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bcp.2020.114149_b0465","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/cancers9070084","article-title":"Integrin alphavbeta3 signaling in tumor-induced bone disease","volume":"9","author":"Kwakwa","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0470","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025461507027","article-title":"Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases","volume":"20","author":"Nemeth","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0475","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/(SICI)1097-0045(19980515)35:3<185::AID-PROS4>3.0.CO;2-G","article-title":"Role of alphaII(b)beta3 integrin in prostate cancer metastasis","volume":"35","author":"Trikha","year":"1998","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.bcp.2020.114149_b0480","first-page":"1655","article-title":"Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway","volume":"59","author":"Zheng","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114149_b0485","first-page":"37","article-title":"Platelet endothelial cell adhesion molecule (CD31)","volume":"184","author":"DeLisser","year":"1993","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0490","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/iju.12840","article-title":"Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: usefulness and limitations of microvessel density measurement","volume":"22","author":"Miyata","year":"2015","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.bcp.2020.114149_b0495","article-title":"Endothelial cell tube formation assay for the in vitro study of angiogenesis","volume":"91","author":"DeCicco-Skinner","year":"2014","journal-title":"J. Vis. Exp."},{"issue":"11","key":"10.1016\/j.bcp.2020.114149_b0500","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0505","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2019.08.006","article-title":"Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer","volume":"155","author":"Liu","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0510","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/IGC.0000000000000946","article-title":"A comparison of survival outcomes in advanced serous ovarian cancer patients treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"27","author":"May","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0515","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/cancers11050615","article-title":"Integrins: moonlighting proteins in invadosome formation","volume":"11","author":"Pelaez","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2020.114149_b0520","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-030-14366-4_12","article-title":"Ovarian cancer stem cell heterogeneity","volume":"1139","author":"Hatina","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0525","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7150\/jca.8610","article-title":"Investigating molecular profiles of ovarian cancer: an update on cancer stem cells","volume":"5","author":"Tomao","year":"2014","journal-title":"J Cancer"},{"key":"10.1016\/j.bcp.2020.114149_b0530","doi-asserted-by":"crossref","first-page":"5263974","DOI":"10.1155\/2017\/5263974","article-title":"The crosstalk between ovarian cancer stem cell niche and the tumor microenvironment","volume":"2017","author":"Varas-Godoy","year":"2017","journal-title":"Stem Cells Int"},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0535","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.24188","article-title":"Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype","volume":"124","author":"Sodek","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0540","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","article-title":"Multicellular spheroids in ovarian cancer metastases: biology and pathology","volume":"113","author":"Shield","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2020.114149_b0545","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub3","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"11","author":"Jaaback","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2020.114149_b0550","first-page":"2803","article-title":"Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer","volume":"29","author":"Zeimet","year":"2009","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0555","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1245\/s10434-013-3277-y","article-title":"Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin","volume":"21","author":"Kwa","year":"2014","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0560","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1245\/s10434-013-3219-8","article-title":"Ovarian cancer: a brief historical overview of intraperitoneal trials","volume":"21","author":"Kwa","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.bcp.2020.114149_b0565","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2019.01.002","article-title":"Panici, Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: a meta-analysis","volume":"136","author":"Marchetti","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0570","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","article-title":"Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment","volume":"24","author":"Markman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.bcp.2020.114149_b0575","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0580","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/GCO.0b013e3283073a6c","article-title":"A review of techniques for adhesion prevention after gynaecological surgery","volume":"20","author":"Metwally","year":"2008","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.bcp.2020.114149_b0585","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jmig.2017.12.010","article-title":"Management, prevention, and sequelae of adhesions in women undergoing laparoscopic gynecologic surgery: a systematic review","volume":"25","author":"Farag","year":"2018","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114149_b0590","first-page":"194","article-title":"Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions","volume":"55","author":"Allen","year":"1987","journal-title":"Exp Cell Biol"},{"issue":"6","key":"10.1016\/j.bcp.2020.114149_b0595","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ijc.2910500627","article-title":"Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation","volume":"50","author":"Bardies","year":"1992","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0600","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.240510307","article-title":"Three-dimensional growth and differentiation of ovarian tumor cell line in high aspect rotating-wall vessel: morphologic and embryologic considerations","volume":"51","author":"Becker","year":"1993","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0605","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<851::AID-IJC23>3.0.CO;2-A","article-title":"Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids","volume":"72","author":"Filippovich","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2020.114149_b0610","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4939-9845-6_10","article-title":"Methods for evaluation of a snake venom-derived disintegrin in animal models of human cancer","volume":"2068","author":"Swenson","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114149_b0615","series-title":"Toxins and Hemostasis","first-page":"301","article-title":"Anti-angiogenesis and disintegrins","author":"Swenson","year":"2010"},{"issue":"suppl. 2","key":"10.1016\/j.bcp.2020.114149_b0620","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2020.114149_b0625","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2020.114149_b0630","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.114149_b0635","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/TCRM.S58289","article-title":"Bevacizumab for glioblastoma","volume":"11","author":"Narita","year":"2015","journal-title":"Ther. Clin. Risk Manage."},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0640","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jocn.2014.05.054","article-title":"Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma","volume":"22","author":"Abrams","year":"2015","journal-title":"J. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.bcp.2020.114149_b0645","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2012.415","article-title":"Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients","volume":"107","author":"Reardon","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2020.114149_b0650","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11910-015-0606-5","article-title":"An overview of alternating electric fields therapy (NovoTTF therapy) for the treatment of malignant glioma","volume":"16","author":"Swanson","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"23","key":"10.1016\/j.bcp.2020.114149_b0655","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bcp.2020.114149_b0660","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3390\/molecules23112918","article-title":"A novel venom-derived peptide for brachytherapy of glioblastoma: preclinical studies in mice","volume":"23","author":"Swenson","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2020.114149_b0665","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1042\/bj0890114","article-title":"The preparation of I-131-labelled human growth hormone of high specific radioactivity","volume":"89","author":"Greenwood","year":"1963","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0670","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11910-005-0047-7","article-title":"Optimal role of temozolomide in the treatment of malignant gliomas","volume":"5","author":"Stupp","year":"2005","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2020.114149_b0675","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:15:53Z","timestamp":1757769353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":135,"alternative-id":["S0006295220303853"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114149","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114149"}}